Compare RYOJ & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYOJ | EVAX |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | Japan | Denmark |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 31.9M |
| IPO Year | N/A | 2020 |
| Metric | RYOJ | EVAX |
|---|---|---|
| Price | $2.41 | $3.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 31.4K | ★ 31.6K |
| Earning Date | 12-15-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $1.20 |
| 52 Week High | $11.43 | $12.15 |
| Indicator | RYOJ | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 48.45 |
| Support Level | $1.89 | $2.45 |
| Resistance Level | $2.39 | $4.64 |
| Average True Range (ATR) | 0.21 | 0.39 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 22.47 | 34.69 |
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.